Press coverage about Corcept Therapeutics (NASDAQ:CORT) has trended somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Corcept Therapeutics earned a news impact score of 0.24 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 46.7133330183378 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

These are some of the media stories that may have effected Accern Sentiment Analysis’s scoring:

Shares of Corcept Therapeutics (CORT) traded down $0.36 during trading on Wednesday, hitting $25.08. The stock had a trading volume of 1,833,583 shares, compared to its average volume of 2,053,294. Corcept Therapeutics has a 1-year low of $6.70 and a 1-year high of $25.76. The firm has a market capitalization of $2,860.00, a P/E ratio of 86.48 and a beta of 1.89.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported $0.11 EPS for the quarter, missing the Zacks’ consensus estimate of $0.13 by ($0.02). Corcept Therapeutics had a return on equity of 58.17% and a net margin of 27.28%. The company had revenue of $42.70 million for the quarter, compared to analyst estimates of $41.64 million. During the same period in the prior year, the firm posted $0.02 earnings per share. The business’s quarterly revenue was up 96.8% compared to the same quarter last year. equities analysts forecast that Corcept Therapeutics will post 0.47 earnings per share for the current fiscal year.

A number of brokerages have recently commented on CORT. Piper Jaffray Companies set a $30.00 price objective on Corcept Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, October 31st. BidaskClub raised Corcept Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Tuesday. Finally, Zacks Investment Research downgraded Corcept Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 3rd. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $21.00.

In related news, insider Robert S. Fishman sold 8,000 shares of the business’s stock in a transaction that occurred on Monday, January 8th. The stock was sold at an average price of $18.67, for a total transaction of $149,360.00. Following the completion of the sale, the insider now owns 8,000 shares in the company, valued at $149,360. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director G Leonard Baker, Jr. sold 30,000 shares of the business’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $17.59, for a total value of $527,700.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 46,000 shares of company stock valued at $810,820. Corporate insiders own 19.20% of the company’s stock.

WARNING: This article was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://theolympiareport.com/2018/01/24/corcept-therapeutics-cort-earning-somewhat-positive-news-coverage-study-shows.html.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR).

Insider Buying and Selling by Quarter for Corcept Therapeutics (NASDAQ:CORT)

Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.